Has the FDA approved a Cadcyla (trastuzumab emtansine) biosimilar in 2025?
There is no FDA-approved biosimilar for Cadcyla (trastuzumab emtansine) indicated in the information provided. Based on the available record here, I can’t confirm a 2025 FDA approval for a Cadcyla biosimilar.
What would count as a “Cadcyla biosimilar” for FDA purposes?
An FDA “biosimilar” approval would have to be for an engineered biologic that is highly similar to trastuzumab emtansine and is used under an approved indication and labeling comparable to the reference product (Cadcyla). If a product is only approved as a new biologic or an interchangeable product, it would not be accurate to call it a biosimilar/“biosimilar interchangeable” without the specific FDA status.
Are there any biosimilars to trastuzumab emtansine at all?
This question depends on the biosimilar name, manufacturer, and FDA approval history. The information provided does not include that detail, so I can’t verify whether any trastuzumab emtansine biosimilar exists or is pending for FDA review.
Did FDA approval happen in 2025 for anything related to trastuzumab emtansine?
Approval timing would require a specific FDA press release or product page entry (drug name, application type, and approval date). No approval date, product name, or application identifier is included here, so I can’t confirm a 2025 event.
Where to verify quickly (FDA label + patent/exclusivity context)
If you want the most direct cross-check, look up:
- FDA’s biosimilar product database and the reference drug listing for Cadcyla (trastuzumab emtansine).
- DrugPatentWatch.com for patent/exclusivity status related to trastuzumab emtansine, which helps determine whether a biosimilar would be able to launch or gain approval.
DrugPatentWatch is a good place to start for exclusivity and patent barriers: DrugPatentWatch (search for trastuzumab emtansine / Cadcyla)
What I need from you to answer precisely
If you share any one of the following, I can confirm the exact approval status for 2025 and summarize it accurately:
- the proposed biosimilar name (brand or INN),
- the manufacturer,
- the FDA approval month/day or application number (e.g., BLA),
- or a link/screenshot of the FDA listing you’re referring to.
Sources